Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Genes & Development
|
September 26, 2013
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
Chong Chen, Yu Liu, Chao Lu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 23, 2011
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability
David R Wise, Patrick S Ward, Jessica E S Shay, et al.
Nature Chemical Biology
|
September 27, 2022
Discovery and molecular basis of subtype-selective cyclophilin inhibitors
Alexander A Peterson, Aziz M Rangwala, Manish K Thakur, et al.
Cancer Discovery
|
February 15, 2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid Leukemia
Alan H Shih, Cem Meydan, Kaitlyn Shank, et al.
Nature
|
February 21, 2012
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, et al.
Cancer Cell
|
February 23, 2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
Patrick S Ward, Jay Patel, David R Wise, et al.
Nature
|
February 21, 2012
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan, Daniel Rohle, Anuj Goenka, et al.
Genes & Development
|
September 26, 2013
Induction of sarcomas by mutant IDH2
Chao Lu, Sriram Venneti, Altuna Akalin, et al.
Nature
|
June 19, 2010
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang, David W White, Stefan Gross, et al.
Nature
|
November 26, 2009
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang, David W White, Stefan Gross, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Genes & Development
|
September 26, 2013
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
Chong Chen, Yu Liu, Chao Lu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 23, 2011
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability
David R Wise, Patrick S Ward, Jessica E S Shay, et al.
Nature Chemical Biology
|
September 27, 2022
Discovery and molecular basis of subtype-selective cyclophilin inhibitors
Alexander A Peterson, Aziz M Rangwala, Manish K Thakur, et al.
Cancer Discovery
|
February 15, 2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid Leukemia
Alan H Shih, Cem Meydan, Kaitlyn Shank, et al.
Nature
|
February 21, 2012
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, et al.
Cancer Cell
|
February 23, 2010
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
Patrick S Ward, Jay Patel, David R Wise, et al.
Nature
|
February 21, 2012
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan, Daniel Rohle, Anuj Goenka, et al.
Genes & Development
|
September 26, 2013
Induction of sarcomas by mutant IDH2
Chao Lu, Sriram Venneti, Altuna Akalin, et al.
Nature
|
June 19, 2010
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang, David W White, Stefan Gross, et al.
Nature
|
November 26, 2009
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang, David W White, Stefan Gross, et al.
Page
of 4